News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Affymax, Inc. (AFFY) and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Announce Preliminary U.S. Registration Strategy for Investigational Drug, Hematide(TM)/Peginesatide, to Treat Anemia in Chronic Renal Failure



8/5/2010 10:33:56 AM

PALO ALTO, Calif. & OSAKA--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the companies have decided on a preliminary strategic path forward for the investigational drug, Hematideā„¢/peginesatide, for the treatment of anemia in chronic renal failure patients in the United States.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES